84.9亿美元资本锚定长寿科技！赛立复力活元让高效抗衰触手可及

Core Insights - The longevity sector is becoming increasingly attractive to global capital, with funding reaching $8.49 billion in the past year, doubling from the previous year [1] - Investors are shifting focus from unrealistic "immortality myths" to projects that can deliver clinical results within 12 to 24 months [1][5] Investment Trends - The 2024 Longevity Investment Report indicates a significant increase in funding for longevity-related projects, reflecting a more rational investment approach [1][5] - Notable investments include Altos Labs focusing on "cellular reprogramming" and Sam Altman investing in Retro Biosciences for "autophagy reboot" drugs [3][5] Scientific Insights - Aging is increasingly viewed as an intervenable process rather than an uncontrollable phenomenon, with NAD+ levels and oxidative stress identified as key factors [5][7] - Research highlights that NAD+ is crucial for energy metabolism and cellular repair, with levels declining significantly after the age of 30 [5][7] Product Development - CELFULL has developed a stable form of NADH, which can directly enhance NAD+ levels and combat oxidative stress, overcoming previous challenges in stability and absorption [10][12] - CELFULL NADH is reported to be four times more effective than traditional NMN supplements, providing a practical solution for aging intervention [12][13] Market Position - CELFULL NADH has gained significant market traction, with over 100,000 users reporting noticeable benefits, and it has maintained the top sales position in its category for over five years [16] - The product aims to make anti-aging solutions accessible to a broader audience, moving beyond high-cost research projects to practical applications for everyday consumers [18]